Interestingly, new treatment options have been proposed for LCNEC, such as chemotherapy based on an SCLC regimen for cases with RB1 loss and cisplatin-based chemotherapy for cases with loss of PTEN or activating mutation of PI3KCA [8, 9]. Here, RB1 is linked to large cell neuroendocrine carcinoma.